ImmuCell Corporation Reports 11.5% Increase in Product Sales for Q2 2026

ImmuCell Corporation reported significant financial performance improvements in its latest quarterly filing, with product sales reaching $7.2 million for the three months ended June 30, 2026, an increase of 11.5% from $6.4 million in the same period last year. For the first half of 2026, total product sales amounted to $17.5 million, reflecting a 20.9% increase compared to $14.5 million in the first half of 2025. The company attributed this growth primarily to higher sales volumes across its First Defense® product line, which constitutes nearly all of its sales, alongside price increases.

The company's gross profit for the second quarter was $2.4 million, down 13.5% from $2.8 million a year earlier, while gross profit for the first half of 2026 was $7.1 million, up 15% from $6.2 million in the prior year. The increase in costs of goods sold, which rose by 30.9% in the second quarter and 25.3% in the first half, was driven by higher sales volumes and a shift of costs associated with the former Re-Tain® manufacturing facility to costs of goods sold. Administrative expenses surged by 76.6% in the second quarter and 79.4% in the first half, largely due to increased executive compensation and professional service fees.

In terms of operational developments, ImmuCell is actively expanding its manufacturing capacity for the First Defense® product line. The company has initiated a program to convert its former Re-Tain® facilities, with the first phase expected to cost approximately $3.5 million and take about 12 months to complete. This expansion aims to enhance production capabilities in response to anticipated demand growth. The company also recorded a $2 million settlement with a former contract manufacturer, which was recognized as other operating income, contributing positively to net income.

As of June 30, 2026, ImmuCell's total assets increased to $46.6 million from $42.5 million at the end of 2025, with cash and cash equivalents rising significantly to $8.9 million. The company reported a net income of $1.8 million for the second quarter, a substantial increase from $501,880 in the same quarter of the previous year, and a net income of $3.8 million for the first half, compared to $1.9 million in 2025. The increase in net income was attributed to improved operational efficiency and the aforementioned settlement.

Looking ahead, ImmuCell anticipates continued growth driven by the expansion of its First Defense® product line and the strategic repurposing of its manufacturing facilities. The company is also monitoring market conditions and customer demand closely, as it aims to enhance its production capabilities to meet future needs. The management remains optimistic about the company's trajectory, although it acknowledges potential risks related to competition and operational challenges.